AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6172332 — intervention group
Group type: EXPERIMENTAL
Intervention: MEVP (methotrexate, cyclophosphamide, vincristine, prednisolone)
Number of subjects: 21
Study 6172332 — intervention group
Group type: EXPERIMENTAL
Intervention: CVPP
Number of subjects: 21
Study 31130060 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 103
Study 31130060 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 103
Study 28390770 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of concentrated bone marrow aspirate (cBMA) via MarrowStim
Number of subjects: 152
Study 28390770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 25881966 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin/bismuth therapy
Number of subjects: 284
Study 25881966 — intervention group
Group type: COMPARATOR
Intervention: BMT quadruple therapy
Number of subjects: 284
Study 23528546 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% polyhexamethylene biguanide dressing (Group A)
Number of subjects: 197
Study 23528546 — intervention group
Group type: COMPARATOR
Intervention: Non-occlusive dressing (Group B)
Number of subjects: 197
Study 21309658 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load (LGL) meals
Number of subjects: 88
Study 21309658 — intervention group
Group type: COMPARATOR
Intervention: High Glycemic Load (HGL) meals
Number of subjects: 88
Study 19482764 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-protected parenteral nutrition (n = 428)
Number of subjects: 866
Study 19482764 — intervention group
Group type: COMPARATOR
Intervention: Light-exposed parenteral nutrition (n = 438)
Number of subjects: 866
Study 17312289 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 281
Study 17312289 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 281
Study 15344424 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 106
Study 15344424 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation (TEAS)
Number of subjects: 106
Study 15344424 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 106
Study 11182041 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2, 3 h) and Carboplatin (AUC 4-5)
Number of subjects: 11
Study 9391999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimegestone, 0.10 mg/day
Number of subjects: 38
Study 9391999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimegestone, 0.25 mg/day
Number of subjects: 38
Study 9391999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trimegestone, 0.50 mg/day
Number of subjects: 38
Study 9391999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17‐beta‐oestradiol, 2 mg/day
Number of subjects: 38
Study 7948238 — intervention group
Group type: COMPARATOR
Intervention: Conventional spike technique (C)
Number of subjects: 100
Study 7948238 — intervention group
Group type: EXPERIMENTAL
Intervention: O-set technique (O)
Number of subjects: 100
Study 7948238 — intervention group
Group type: EXPERIMENTAL
Intervention: UVXD technique (U)
Number of subjects: 100
Study 3371480 — intervention group
Group type: EXPERIMENTAL
Intervention: Home insemination
Number of subjects: 53
Study 3371480 — intervention group
Group type: COMPARATOR
Intervention: Clinic insemination
Number of subjects: 53
Study 3371480 — intervention group
Group type: EXPERIMENTAL
Intervention: Home insemination (in couples who did not meet criteria)
Number of subjects: 53
Study 28492428 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain gut suture
Number of subjects: 49
Study 28492428 — intervention group
Group type: COMPARATOR
Intervention: PG910 (Vicryl) suture
Number of subjects: 49
Study 26805433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inosine
Number of subjects: 0
Study 26805433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25611939 — intervention group
Group type: EXPERIMENTAL
Intervention: Playworks
Number of subjects: 29
Study 25611939 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study 22503993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional weight loss (WL)
Number of subjects: 3
Study 20873243 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone (n=46)
Number of subjects: 182
Study 20873243 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and gliclaside MB (n=47)
Number of subjects: 182
Study 20873243 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and insulin (n=44)
Number of subjects: 182
Study 20873243 — intervention group
Group type: COMPARATOR
Intervention: Insulin (n=45)
Number of subjects: 182
Study 18954638 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricle-pulmonary artery shunt
Number of subjects: 0
Study 18954638 — intervention group
Group type: COMPARATOR
Intervention: Modified Blalock-Taussig shunt
Number of subjects: 0
Study 16351785 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP regimen
Number of subjects: 63
Study 16351785 — intervention group
Group type: COMPARATOR
Intervention: CHOP regimen
Number of subjects: 63
Study 12477585 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 50
Study 12477585 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine and ketamine (1 mg/mL)
Number of subjects: 50
Study 12477585 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine group
Number of subjects: 50
Study 12477585 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-ketamine group
Number of subjects: 50
Study 12477585 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-ketamine
Number of subjects: 50
Study 10361873 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid sodium (750 anti-Xa units once daily for 8 weeks)
Number of subjects: 22
Study 10361873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8572838 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril maleate, 10 mg/d for 5 years
Number of subjects: 94
Study 8572838 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 years
Number of subjects: 94
Study 1767693 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Practice Clinic Patient Medical Advisor Booklet and an educational presentation
Number of subjects: 0
Study 1767693 — intervention group
Group type: COMPARATOR
Intervention: Family Practice Clinic Patient Medical Advisor Booklet
Number of subjects: 0
Study 7081684 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 30 mg/kg administered following induction of anaesthesia and repeated with the start of cardiopulmonary bypass
Number of subjects: 0
Study 7081684 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 0
Study 31041855 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin (8 to 24 mg/d)
Number of subjects: 265
Study 31041855 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (4 to 12 mg/d)
Number of subjects: 265
Study 29310989 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in HDL-cholesterol measurements
Number of subjects: 9572
Study 29310989 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in triglyceride measurements
Number of subjects: 9572
Study 29310989 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in LDL-cholesterol measurements
Number of subjects: 9572
Study 29310989 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in triglyceride and LDL-cholesterol measurements
Number of subjects: 9572
Study 29310989 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in HDL-cholesterol, triglycerides, and LDL-cholesterol
Number of subjects: 9572
Study 27083200 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 33
Study 27083200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 33
Study 27083200 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture + Cognitive Behavioural Therapy (EA+CBT)
Number of subjects: 33
Study 27083200 — intervention group
Group type: COMPARATOR
Intervention: Untreated Control
Number of subjects: 33
Study 24803302 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 181 (210 mg s.c.)
Number of subjects: 72
Study 24803302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 24803302 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 181 (various doses: 0.7, 2.1, 7, 21, 70 mg s.c. or i.v., 210 mg s.c. or i.v., 420 mg i.v.)
Number of subjects: 72
Study 24803302 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 181 (various doses)
Number of subjects: 72
Study 24712204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefalotin for 24 hours plus ten additional days of dicloxacillin (Group I)
Number of subjects: 131
Study 24712204 — intervention group
Group type: COMPARATOR
Intervention: Cefalotin for 24 hours and placebo for ten days (Group II)
Number of subjects: 131
Study 19348675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane + fentanyl
Number of subjects: 411
Study 19348675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane + remifentanil
Number of subjects: 411
Study 19348675 — intervention group
Group type: COMPARATOR
Intervention: Propofol + remifentanil
Number of subjects: 411
Study 16926662 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (500 IU per day)
Number of subjects: 409
Study 16926662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 14635749 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose (inj. hydrocortisone 100 mg IV 6‐hourly for 3 days)
Number of subjects: 130
Study 14635749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose (inj. hydrocortisone 100 mg IV 6‐hourly on day 1, 100 mg IV 8‐hourly on day 2, and 100 mg IV 12‐hourly on day 3)
Number of subjects: 130
Study 14635749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose protocol (inj. hydrocortisone 25 mg IV 6‐hourly on day 1, 25 mg IV 8‐hourly on day 2 and 25 mg IV 12‐hourly on day 3)
Number of subjects: 130
Study 14635749 — intervention group
Group type: COMPARATOR
Intervention: Not receiving hydrocortisone (Group II)
Number of subjects: 130
Study 11304719 — intervention group
Group type: EXPERIMENTAL
Intervention: r-HuEPO with new stabilizer (glycine and Polysorbate 80) at 150 IU/kg sc dose
Number of subjects: 24
Study 11304719 — intervention group
Group type: EXPERIMENTAL
Intervention: r-HuEPO with new stabilizer (glycine and Polysorbate 80) at 750 IU/kg sc dose
Number of subjects: 24
Study 11304719 — intervention group
Group type: COMPARATOR
Intervention: r-HuEPO without new stabilizer (HSA) at 150 IU/kg sc dose
Number of subjects: 24
Study 11304719 — intervention group
Group type: COMPARATOR
Intervention: r-HuEPO without new stabilizer (HSA) at 750 IU/kg sc dose
Number of subjects: 24
Study 11304719 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (with and without new stabilizer)
Number of subjects: 24
Study 8852315 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with muscle pain
Number of subjects: 20
Study 8852315 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of perceived muscle tension by patients with muscle pain
Number of subjects: 20
Study 8852315 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 20
Study 1468693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and cyclophosphamide with or without doxorubicin
Number of subjects: 349
Study 1468693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Number of subjects: 349
Study 1468693 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial extrapelvic disease
Number of subjects: 349
Study 6420161 — intervention group
Group type: EXPERIMENTAL
Intervention: Chap‐5 (adriamycin, cis‐dichlorodiammine platinum (II), hexamethylmelamine, cyclophosphamide)
Number of subjects: 22
Study 6420161 — intervention group
Group type: COMPARATOR
Intervention: Hexa CAF (methotrexate, 5‐fluorouracil, hexamethylmelamine, cyclophosphamide)
Number of subjects: 22
Study 6420161 — intervention group
Group type: EXPERIMENTAL
Intervention: Chap‐5
Number of subjects: 22
Study 6420161 — intervention group
Group type: COMPARATOR
Intervention: Hexa CAF
Number of subjects: 22
Study 31492718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladostigil 10 mg/d
Number of subjects: 210
Study 31492718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 29966612 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 μg, 4 times daily; n = 42)
Number of subjects: 84
Study 29966612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 42)
Number of subjects: 84
Study 29966612 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 84
Study 26721775 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay (LOS)
Number of subjects: 1347
Study 24650820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription drug misuse (PDM) of one class
Number of subjects: 2127
Study 24650820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription drug misuse (PDM) of two classes
Number of subjects: 2127
Study 24650820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription drug misuse (PDM) of three classes
Number of subjects: 2127
Study 24650820 — intervention group
Group type: COMPARATOR
Intervention: No prescription drug misuse (PDM)
Number of subjects: 2127
Study 22795277 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 7500
Study 22795277 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 7500
Study 20166864 — intervention group
Group type: EXPERIMENTAL
Intervention: Three early structured telephone interventions (n=81)
Number of subjects: 131
Study 20166864 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=50)
Number of subjects: 131
Study 17094975 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching
Number of subjects: 199
Study 17094975 — intervention group
Group type: COMPARATOR
Intervention: Control (no assisted hatching)
Number of subjects: 199
Study 16219020 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant leptin (10 mg/morning, 10 mg/evening, or 20 mg/day)
Number of subjects: 284
Study 16219020 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant leptin
Number of subjects: 284
Study 16219020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 11966742 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement
Number of subjects: 32
Study 11966742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9927014 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 50% of VO2peak
Number of subjects: 6
Study 9927014 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 70% of VO2peak
Number of subjects: 6
Study 9927014 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) during 50% and 70% trials
Number of subjects: 6
Study 9927014 — intervention group
Group type: COMPARATOR
Intervention: Comparison of N and C
Number of subjects: 6
Study 7754943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing
Number of subjects: 214
Study 7754943 — intervention group
Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 214
Study 7754943 — intervention group
Group type: COMPARATOR
Intervention: No pacing therapy
Number of subjects: 214
Study 1701097 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% dextran 70 (Dx70)
Number of subjects: 40
Study 1701097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate
Number of subjects: 40
Study 7428183 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (acute administration)
Number of subjects: 0
Study 7428183 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (acute administration)
Number of subjects: 0
Study 7428183 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (further treatment)
Number of subjects: 0
Study 7428183 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (prolonged administration)
Number of subjects: 0
Study 31836949 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks (first three doses every 4 weeks)
Number of subjects: 0
Study 31836949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30529157 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve infiltration with 10 mL of 0.25% bupivacaine
Number of subjects: 90
Study 30529157 — intervention group
Group type: COMPARATOR
Intervention: No phrenic nerve infiltration (control)
Number of subjects: 90
Study 28845577 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 112
Study 28845577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 26860018 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg) administered orally two hours before surgery
Number of subjects: 70
Study 26860018 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (400 mg) administered orally two hours before surgery
Number of subjects: 70
Study 26860018 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between Meloxicam and Celecoxib
Number of subjects: 70
Study 23001685 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 23001685 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 0
Study 23001685 — intervention group
Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 0
Study 21107599 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise before diving (Ex)
Number of subjects: 24
Study 21107599 — intervention group
Group type: COMPARATOR
Intervention: Control dive without exercise before (No-Ex)
Number of subjects: 24
Study 19245735 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 long-chain PUFA-supplemented dairy products
Number of subjects: 45
Study 19245735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 16400707 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 101
Study 16400707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 12616437 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 74
Study 12616437 — intervention group
Group type: COMPARATOR
Intervention: Open hemorrhoidectomy (Milligan-Morgan technique)
Number of subjects: 74
Study 10831636 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and cyclophosphamide
Number of subjects: 20
Study 10831636 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 20
Study 9360754 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid electrolytic water (AEW)
Number of subjects: 22
Study 9360754 — intervention group
Group type: COMPARATOR
Intervention: Tap water (placebo)
Number of subjects: 22
Study 1492847 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed effervescent granules (Imbun) containing 500 mg ibuprofen lysine salt (292.6 mg ibuprofen)
Number of subjects: 12
Study 1492847 — intervention group
Group type: COMPARATOR
Intervention: Commercially available granules containing 600 mg ibuprofen
Number of subjects: 12
Study 1492847 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed effervescent granules (Imbun)
Number of subjects: 12
Study 1492847 — intervention group
Group type: COMPARATOR
Intervention: Commercially available granules
Number of subjects: 12
Study 1492847 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 12
Study 3884358 — intervention group
Group type: EXPERIMENTAL
Intervention: S-R theophylline preparation given once each night (mean 11.2 mg/kg/day)
Number of subjects: 9
Study 3884358 — intervention group
Group type: COMPARATOR
Intervention: S-R aminophylline preparation every 12 h (mean 10.3 mg theophylline/kg/day)
Number of subjects: 9
Study 30840576 — intervention group
Group type: EXPERIMENTAL
Intervention: Less invasive technique (Group 2)
Number of subjects: 71
Study 30840576 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (Group 1)
Number of subjects: 71
Study 26696365 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI group (lansoprazole 15 mg twice daily for 2 months)
Number of subjects: 48
Study 26696365 — intervention group
Group type: COMPARATOR
Intervention: Non-PPI group
Number of subjects: 48
Study 25058680 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r) monotherapy
Number of subjects: 103
Study 25058680 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATV/r) along with two NRTIs
Number of subjects: 103
Study 22901923 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (40 mg/kg)
Number of subjects: 100
Study 20142295 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5-inch needle
Number of subjects: 0
Study 20142295 — intervention group
Group type: COMPARATOR
Intervention: 1-inch needle
Number of subjects: 0
Study 17908886 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization in external rotation for three weeks
Number of subjects: 198
Study 17908886 — intervention group
Group type: COMPARATOR
Intervention: Immobilization in internal rotation for three weeks
Number of subjects: 198
Study 16109088 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg alendronate, taken once a week for 6 weeks
Number of subjects: 31
Study 16109088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12075559 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic apheresis
Number of subjects: 85
Study 12363060 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 50 mg/kg
Number of subjects: 129
Study 12363060 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 25 mg/kg
Number of subjects: 129
Study 9513587 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized furosemide (40 mg)
Number of subjects: 42
Study 9513587 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 42
Study 7817807 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol for 2 years
Number of subjects: 30
Study 7817807 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched males (control)
Number of subjects: 30